HKG Equity Snapshot
2616 Weekly Equity Report
CStone Pharmaceuticals
What the company does
CStone Pharmaceuticals, a biopharmaceutical company, researches and develops anti-cancer therapies to address the unmet medical needs of cancer patients in Mainland China and internationally. The company offers CEJEMLY (sugemalimab), a monoclonal antibody against programmed death (PD) ligand 1 for the treatment of non-small cell lung cancer (NSCLC), gastric adenocarcinoma/gastroesophageal junction adenocarcinoma, esophageal squamous cell carcinoma, and relapsed or refractory natural killer/T cell lymphoma; GAVRETO (pralsetinib), a RET inhibitor to treat patients with advanced or metastatic RET-mutant medullary and RET fusion-positive thyroid cancers, as well as NSCLC and multiple tumors; and AYVAKIT (avapritinib), a KIT/PDGFRA inhibitor, …
What the weekly tape is saying
2616 closed the latest completed week at 4.67 HKD. The 4-week return is -42.3% and the 12-week return is -31.8%. Trend Signal is inactive, Market Dynamics is -0.58. Setup signature: Risk-first tape with a 15/100 composite read.
A compressed read of the whole setup
The radar blends trend persistence, momentum, Market Dynamics, Relative Strength, volume confirmation, and risk control into one weekly cockpit.
Scoreboard
16-week signal tape
Price, Trend Line, and Fair Value
Weekly price context with the latest close, trend position, Fair Value gap, drawdown, and 52-week range location.
52-week price path
Price map
- Trend Line
- 6.89 HKD
- Vs Trend Line
- -32.2%
- Fair Value
- 3.72 HKD
- Vs Fair Value
- 25.6%
- 52W High
- 13.15 HKD
- 52W Low
- 3.91 HKD
- Drawdown
- -64.5%
- Range Position
- 8.2%
Returns and trend persistence
Return windows separate the latest week from short-term and medium-term follow-through.
Return windows
Trend read
- Active Streak
- 0 weeks
- 52W Active Weeks
- 29
- 52W Active Breadth
- 55.8%
- Sector Scope
- HK Healthcare
- Sector Rank
- 109 of 257
- Sector Percentile
- 57.8%
Sector and industry pulse
Peer breadth helps separate a stock-specific move from a broader group rotation.
HK Healthcare
- Tracked Peers
- 100
- 4W Rank
- 98 of 100
- Avg 1W
- -1.3%
- Avg 4W
- -12.8%
- Trend Breadth
- 6.0%
- Positive MD
- 10.0%
HK Biotechnology
- Tracked Peers
- 76
- 4W Rank
- 74 of 76
- Avg 1W
- -1.6%
- Avg 4W
- -17.5%
- Trend Breadth
- 3.9%
- Positive RS
- 5.3%
Pressure, Relative Strength, and expectation
Market Dynamics and Relative Strength show whether buying pressure and relative leadership are confirming the price move.
Dynamics path
Signal state
- Market Dynamics
- -0.58
- 4W MD Change
- -176.6%
- Relative Strength
- -31.19
- 4W RS Change
- -292.5%
- Expectation
- Undecided
- Probability
- 47.21%
Participation and confirmation
Volume tells us whether the latest weekly move is being confirmed by unusual participation.
52-week volume profile
Volume map
- Latest Volume
- 57.9M
- 13W Average
- 68.7M
- 52W Average
- 71.2M
- Vs 13W
- 0.8x
- Vs 52W
- 0.8x
Volatility, downside weeks, and return shape
A compact risk profile shows whether the move is steady, volatile, or being driven by sharp one-week jumps.
26-week return distribution
Risk map
- 13W Volatility
- 13.9%
- 52W Volatility
- 12.2%
- Upside Weeks
- 26
- Downside Weeks
- 26
- Downside Breadth
- 50.0%
- Avg Gain / Loss
- 10.1% / -8.4%
Classification, opportunities, risks, and watch points
Top-level read across company classification, constructive evidence, caution points, and the next things that matter.
Classification
- Exchange
- HKG
- Country
- HK
- Sector
- Healthcare
- Industry
- Biotechnology
- Currency
- HKD
- Market Cap
- 8.7B
Opportunity signals
- Price is above Fair Value, showing premium demand versus the model.
Risk signals
- Trend Signal is inactive, so price action has not confirmed a constructive regime.
- Price is below the Trend Line, which keeps downside pressure in focus.
- Market Dynamics is negative, which weakens the current setup.
- The share remains more than 20% below its 52-week high.
Watch next
- Trend Line remains the key weekly regime level.
- Market Dynamics is the pressure gauge to monitor for confirmation or fade.
- A volume ratio above 1.5x would show stronger participation in the next move.
Recent completed weeks
The latest weekly rows behind the report snapshot.
| Week | Close | Return | Trend | Fair Value | MD | RS | Volume | Signal |
|---|---|---|---|---|---|---|---|---|
| 12 Jun 2026 | 4.67 HKD | -0.6% | 6.89 HKD | 3.72 HKD | -0.58 | -31.19 | 57.9M | Off |
| 5 Jun 2026 | 4.70 HKD | -41.6% | 6.94 HKD | 3.71 HKD | -0.22 | -31.44 | 152.3M | On |
| 29 May 2026 | 8.05 HKD | 0.4% | 6.96 HKD | 3.69 HKD | 0.08 | 16.60 | 30.9M | On |
| 22 May 2026 | 8.02 HKD | -0.9% | 6.90 HKD | 3.66 HKD | 0.40 | 15.45 | 27.0M | On |
| 15 May 2026 | 8.09 HKD | -4.1% | 6.84 HKD | 3.63 HKD | 0.76 | 16.20 | 45.9M | On |
| 8 May 2026 | 8.44 HKD | -9.2% | 6.80 HKD | 3.59 HKD | 1.12 | 20.89 | 43.5M | On |
| 1 May 2026 | 9.30 HKD | -3.9% | 6.75 HKD | 3.56 HKD | 1.34 | 38.41 | 34.2M | On |
| 24 Apr 2026 | 9.68 HKD | -4.2% | 6.70 HKD | 3.52 HKD | 1.55 | 45.44 | 55.6M | On |
| 17 Apr 2026 | 10.10 HKD | 0.3% | 6.63 HKD | 3.48 HKD | 1.66 | 53.49 | 82.1M | On |
| 10 Apr 2026 | 10.07 HKD | 7.7% | 6.58 HKD | 3.44 HKD | 1.51 | 57.85 | 47.7M | On |
| 3 Apr 2026 | 9.35 HKD | 12.2% | 6.57 HKD | 3.40 HKD | 1.45 | 54.41 | 104.5M | Off |
| 27 Mar 2026 | 8.33 HKD | 21.6% | 6.67 HKD | 3.36 HKD | 1.22 | 41.15 | 129.0M | Off |
| 20 Mar 2026 | 6.85 HKD | -3.7% | 6.75 HKD | 3.33 HKD | 1.05 | 16.37 | 82.7M | Off |
| 13 Mar 2026 | 7.11 HKD | 6.9% | 6.85 HKD | 3.31 HKD | 0.77 | 21.10 | 65.2M | Off |